REG - Allergy Therapeutics - UK manufacturing update

Allergy TherapeuticsAnnouncement

04/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221004:nRSD6381Ba&default-theme=true

RNS Number : 6381B  Allergy Therapeutics PLC  04 October 2022

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

 

Allergy Therapeutics proactively initiates a short-term pause in UK
manufacturing to optimise quality systems and accelerate capacity improvements

 

 

04 October 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergen immunotherapy, today
announces that it has proactively paused production at the Freeman facility,
part of its Worthing, UK manufacturing site, in order to accelerate ongoing
site improvements. No areas for improvement are related to the safety of
products and all of the Group's clinical trials remain unaffected.

 

The partial pause in production follows an internal review of current
operating processes and is part of the Group's previously communicated ongoing
programme to improve the robustness of its quality systems and build capacity
across its manufacturing facilities.

 

Work is ongoing to minimise the commercial impact. We currently believe the
pause in production will be confined to a number of weeks and we are working
to limit the impact on revenue in that period.

 

Manuel Llobet, CEO at Allergy Therapeutics, stated: "This temporary pausing
of production is a necessary step to ensure that we can both continue to
deliver the highest standards of quality in our products and build capacity
for the future growth of the Group. It does not affect the safety of our
products. Our work to deliver ongoing improvements has identified a number of
systems that require further optimisation. Accelerating this work will ensure
Allergy Therapeutics is fit for the future across its growing portfolio.

 

"We continue to support our strong R&D driven pipeline. Our clinical
trials remain on track and are completely unaffected by these manufacturing
improvements."

 

 

This announcement contains inside information for the purposes of Article 7 of
Regulatory (EU) No596/2014.

 

- ENDS -

 

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which,
employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY).
For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSUFUDEESEIS